Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 3/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.48 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.48 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.48 |
| ▸ | LTA4H | P09960 | 3/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 6/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5863430 | 0.85 | HTT (0.55) | PDK1PDK2PDK3PDK4LTA4H | |
| SCHEMBL5863865 | 0.82 | PDK1 (0.44) | PDK1PDK2PDK3PDK4LTA4H | |
| SCHEMBL5864005 | 0.81 | LTA4H (0.47) | PDK1LTA4HKDRHTTKCNH2 | |
| SCHEMBL5863666 | 0.80 | ESR1 (0.51) | PDK1PDK2PDK3PDK4LTA4H | |
| SCHEMBL5863869 | 0.78 | LTA4H (0.48) | LTA4HKDRHTTKCNH2MCHR1 | |
| SCHEMBL5863563 | 0.78 | LTA4H (0.48) | LTA4HKDRHTTKCNH2MCHR1 | |
| SCHEMBL5864070 | 0.78 | LTA4H (0.43) | PDK1PDK2PDK3PDK4LTA4H | |
| SCHEMBL5863929 | 0.78 | PGR (0.54) | LTA4HKDRHTTKCNH2MCHR1 | |
| SCHEMBL5863991 | 0.76 | NR3C1 (0.50) | LTA4HHTTKCNH2MCHR1ESR1 | |
| SCHEMBL5864229 | 0.76 | LTA4H (0.45) | PDK1LTA4HKDRHTTKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053212-B2 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC. (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1542967-A1 | AMIDE AND SULFONAMIDE LIGANDS FOR THE ESTROGEN RECEPTOR | Pfizer Products Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC | 2004-06-10 | — | — | US | disclosed |
| WO-2004026823-A1 | AMIDE AND SULFONAMIDE LIGANDS FOR THE ESTROGEN RECEPTOR | PFIZER PRODUCTS INC. (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | GHSR, GPER1, SSTR1 | PDK1 3468/4885PDK2 4004/4885PDK3 4168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.